Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report
- 1.2k Downloads
The Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer published its first report in July 2013 on the epidemiological assessment of the associations of diabetes with cancer risk/prognosis, the common risk factors for diabetes and cancer, and cancer risk associated with diabetes treatment The JDS/JCA Joint Committee continued its work to assess the role of glycemic control in the development of cancer in patients with diabetes. This review shows that high-quality evidence examining the association between glycemic control and cancer risk is lacking.
KeywordsDiabetes Cancer Glucose control HbA1c Randomized controlled trials Observational studies
Compliance with ethical standards
Conflict of interest
Hiroshi Noto received honoraria for manuscripts from Eli Lilly Japan K.K. Mitsuhiko Noda received scholarship grants from Takeda Pharmaceutical Company Limited and AstraZeneca K. K. Kohjiro Ueki received speaker honoraria from MSD K.K, scholarship grants from Takeda Pharmaceutical Company Limited, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc., Sanofi K. K, Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K, MSD K.K, Boehringer Ingelheim, Mitsubishi-Tanabe Pharma Corporation and courses endowed by MSD K.K, Boehringer Ingelheim and Novo Nordisk Pharma Ltd. Naoko Tajima received speaker honoraria from Astellas Pharma Inc., MSD K.K, Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly Japan K.K, Boehringer Ingelheim and Novo Nordisk Pharma Ltd. Nobuyuki Hamajima received scholarship grants from Sugi Drugstore Co. Ltd. Kohzoh Imai received research grants from DeNA Life Science. Inc. Hitoshi Nakagama received research grants from Shimadzu Corporation and BioMimetics Sympathies Inc. Atsushi Goto, Masato Kasuga, Ken Ohashi, Ryuichi Sakai, Shoichiro Tsugane and Kazuo Tajima declare that they have no conflict of interest.
- 13.Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.CrossRefPubMedGoogle Scholar